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Epithelial cell adhesion molecule (EpCAM) is a cell-
surface protein highly expressed in embryonic tis-
sues and in malignant carcinomas. We report that
EpCAM acts as a potent inhibitor of novel protein
kinase C (nPKC) in both embryos and cancer cells.
We observed dramatic effects of loss of EpCAM
on amphibian embryonic tissues, which include
sequentially strong overstimulation of PKC activity
and of the Erk pathway, leading to exacerbated
myosin contractility, loss of cadherin-mediated
adhesion, tissue dissociation, and, ultimately, cell
death. We show that PKC inhibition is caused by a
short segment of the EpCAM cytoplasmic tail. This
motif resembles the pseudosubstrate inhibitory
domains of PKCs and binds nPKCs with high affinity.
A bioinformatics search reveals the existence of
similar motifs in other plasma membrane proteins,
most of which are cell-cell adhesion molecules.
Thus, direct inhibition of PKC by EpCAM represents
a general mode of regulation of signal transduction
by cell-surface proteins.
INTRODUCTION
Epithelial cell adhesion molecule (EpCAM) was initially discov-
ered as a cell-surface antigen highly expressed in a variety of
carcinomas. It is currently considered to be an important carci-
noma marker and a promising target for immunotherapy of
several malignancies (Munz et al., 2009; Patriarca et al., 2012;
Seimetz et al., 2010; Visvader and Lindeman, 2008). ‘‘EpCAM’’
relates to its restricted expression in adult human and mice
epithelia and its ability to bind homophilically (Litvinov et al.,
1994). EpCAM and the closely related EpCAM-2/EGP-1/Trop-2
(Cubas et al., 2009) have thus been classified as unique Ca2+-in-
dependent cell-cell adhesion molecules unrelated to any of the
major families of CAMs. They are characterized by an extracel-
lular domain with two EGF domains, a single transmembrane
domain, and by a very short (24 amino acids) cytoplasmic tail.
EpCAM has been highly conserved in vertebrates, but no
obvious homologs are found outside of this subphylum. Single
EpCAM knockout in mice and EpCAM null mutants in ZebrafishDevelopmegive relatively weak embryonic phenotypes (Lei et al., 2012;
Slanchev et al., 2009; Villablanca et al., 2006), although in one
report it seemed to cause mouse embryonic lethality through
placental defects (Nagao et al., 2009). It is likely that the second
EpCAM gene present in both species (Q568H0 in Zebrafish,
called here EpCAM-2) functions redundantly. Phenotypes for
complete loss-of-function of both EpCAMs have yet to be
reported.
High EpCAM levels have been long suspected to play an
important role in cancer development and invasion, and it has
been indeed found to increase proliferation and migration of
tumor cell lines (Mu¨nz et al., 2004; Osta et al., 2004). The prolif-
erative action of EpCAM has been attributed to the ability of its
short cytoplasmic tail to form a transcription activator complex
with FHL2 and b-Catenin (Maetzel et al., 2009). This association
occurs in the nucleus and is thus conditional to the release of the
cytoplasmic domain as a soluble proteolytic fragment by the
sequential action of TNF-aconverting enzyme (TACE) and pre-
senilin-2 (Maetzel et al., 2009). This mechanism, however, may
not be general but rather restricted to some cancer cells, de-
pending perhaps on EpCAM levels and expression of the rele-
vant proteolytic enzymes (Denzel et al., 2009).
As for its role in migration, in vivo supporting data have been
scarce, except for a report of impaired migration of skin Langer-
hans cells in conditionally knocked-out mice (Gaiser et al., 2012).
In both Zebrafish and Xenopus embryos, EpCAM depletion
affects epiboly, a morphogenetic process through which the
ectoderm thins and expands during gastrulation (Slanchev
et al., 2009). That cell migration and/or tissue rearrangement
would be promoted by a protein assumed to function as cell-
cell adhesion is quite counterintuitive. The fact that EpCAM
expression caused increased cadherin levels (Maghzal et al.,
2010; Slanchev et al., 2009) further added to the puzzle. It comes
to no surprise that in the absence of a mechanistic understand-
ing of EpCAM function the various proposed models have been
inconsistent and contradictory. While we confirmed and
strengthened the observations that EpCAM positively regulates
both cell movements and cadherin levels, we demonstrated
that regulation of cell motility occurred independently of the sta-
bilization of cadherins (Maghzal et al., 2010). Most strikingly, it
also appeared to be independent of the presumed adhesive
function of EpCAM: Indeed, motility and normal epiboly could
be rescued in EpCAM-depleted tissues/embryos by expression
of an EpCAM construct lacking the whole extracellular domain
(Maghzal et al., 2010). These results implied that EpCAM had a
signaling activity, which we confirmed by showing that EpCAMntal Cell 27, 263–277, November 11, 2013 ª2013 Elsevier Inc. 263
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Figure 1. EpCAM Is Required for Maintenance of Tissue Integrity during Xenopus Development
(A–C) External embryo phenotype, tailbud stage. Compared to embryos injected with control morpholinos (A, COMO), EpCAM-depleted embryos (B, EpCAM
MO) were generally shorter, which can be attributed to impairedmorphogenetic movements. Most of them (>90%) displayed epidermal lesions out of which loose
cells leaked out (arrows and inserts B0 and B00). The lesions invariably expanded and the entire embryo disintegrated (B, last embryo to the bottom). (C) Normal
development was largely rescued by coinjection of mRNA coding for EpCAM with an upstream coding sequence not recognized by the morpholinos. Identical
phenotypes were observed in at least five independent experiments (quantification in Figure S1B).
(D–J0 ) Analysis of the inner structure of mosaic embryos. Mosaics were obtained by MO injection in one blastomere at the 16-cell stage. mRNA coding for
membrane-targeted GFP (mGFP) was coinjected to trace the injected cells. Sagittal sections were stained for GFP (green) and for C-cadherin (red). Identical
phenotypes were observed in five (D–I) and three (J) independent experiments. (D and G) General views of the dorsal side of control (COMO) and EpCAM-
depleted tailbud stage embryos. Many EpCAM-depleted cells were expelled out of the tissues and even out of the embryo (arrowheads). Those remaining in the
tissues appeared poorly integrated (arrows). Scale bars, 100 mm. (E and H) Enlarged details of the dorsal side. Most EpCAM-depleted cells were located at the
(legend continued on next page)
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Direct Inhibition of PKC by EpCAMcontrolled the activity of the so-called novel PKCs (nPKCs) and
thus moderated actomyosin-based contractility.
How EpCAM regulated cadherin levels and cell-cell adhesion,
in particular whether this function also relied on repression of
PKC activity was an important issue that remained to be estab-
lished. The mechanism that led to PKC inhibition was certainly
the most puzzling and exciting question, especially considering
the dramatic effect of EpCAM levels on total cellular PKC activity,
which positioned EpCAM as a major regulator of intracellular
signaling.
RESULTS
EpCAM Is Required for Tissue Integrity
EpCAM is broadly expressed in all three germ layers of the early
embryo, but is particularly abundant in the ectoderm (Figure S1A
available online). Large changes were observed in specific tis-
sues at late embryonic stages, indicating active regulation (Fig-
ure S1A). Global depletion of EpCAM by injection of antisense
Morpholino oligonucleotides (EpCAM MO) caused Xenopus
embryonic lethality with strong penetrance (>90%; Figure S1B).
Tailbud stage embryos showed numerous morphological de-
fects, including a shortened body axis and head malformations
(Figure 1B); however, the most dramatic effect of EpCAM
depletion was the appearance at the early tailbud stage of large
superficial lesions of the epidermis (Figure 1B, arrows), which
eventually led in all cases to its disintegration (Figure 1B, lower
embryo). Coinjection of EpCAMmRNA lacking the 50 UTR region
recognized by EpCAM MO rescued epidermal integrity and
largely restored normal morphology, demonstrating the speci-
ficity of these oligonucleotides (Figure 1C). Analysis of mosaic
embryos showed that the phenotype was cell autonomous (Fig-
ures 1E–1J): EpCAM MO-injected cells were rounder (Figures
1G–1I) and had a weaker C-Cadherin staining (Figures 1H0 and
1I0) than neighboring wild-type cells or cells injected with control
morpholinos (COMO; Figures 1D–1F). Many EpCAM-depleted
cells were detached and had been expelled from the tissue (Fig-
ures 1G–1I, arrowheads), which correlated with a nearly com-
plete loss of cadherin (arrowheads in Figures 5H0 and 5I0). The
decrease in cadherin was detected before overt changes in
cell shape and dissociation (Figures 1J and 1J0), suggesting
that the former may be causal to the latter. All tissues
(ectoderm, neuroderm, mesoderm derivatives, and endoderm)
were affected, although dissociation of the ectoderm occurred
earlier and was more complete. Thus, EpCAM appeared to be
crucially required for tissue integrity.
Because EpCAM-depletion affected to different degree the
development of the various tissues, we used ectoderm explants
as a simpler system to further investigate the cellular function of
EpCAM (Figure 2A): When the prospective ectoderm is ex-
planted out of a blastula embryo, it heals into a ball made ofperiphery of the tissue and were round (H, arrowheads). Even cells still surroun
polygonal shape characteristic of normal adherent cells (concave arrowhead). (
EpCAM-MO-injected cells. Scale bars, 20 mm. (F and I) Ventral side, tailbud stage
EpCAM-depleted cells (arrowheads). (J and J0) EpCAM MO-injected cells stil
decreased cadherin staining, in all types of tissues (on this section neuroderm, m
and wild-type groups. ar, archenteron roof; ec, ectoderm; en, endoderm; me, m
See also Figure S1.
Developmethe outer pigmented layer surrounding an inner mass of unpig-
mented cells. Because these explants are now isolated from
patterning signals, they remain pure ectoderm, and can bemain-
tained in vitro in this state for up to 3 days, i.e., past the time of
hatching of control embryos. Ectoderm explants from EpCAM
MO-injected embryos started to burst at the same time as
lesions appeared on whole embryos (Figure 2A00). EpCAM deple-
tion equally affected outer and inner cells (Figures S2A–S2C).
Furthermore, consistent with the whole embryo phenotype,
C-Cadherin protein levels were strongly decreased in EpCAM
MO explants (Figure 2C). The ‘‘loss of epithelial integrity’’ pheno-
type (LEI) could thus be readily quantified by counting the num-
ber of bursting ectoderm explants. Typically, the incidence of LEI
in EpCAM-depleted explants in our standard procedure was
approximately 80%–90% (Figure 2B). It was rescued by coinjec-
tion of Xenopus or human EpCAM mRNA (Figure 2B). Two trun-
cated mutants lacking respectively the C-terminal tail (DC) and
the extracellular domain (DE) failed to rescue LEI, indicating
that both parts of the protein were required for its function (Fig-
ure 2B). We then asked whether downregulation of C-Cadherin
was sufficient to explain the LEI in EpCAM-depleted ectoderm.
C-Cadherin overexpression was indeed sufficient to rescue LEI
(Figure 2B), consistent with LEI being a simple direct conse-
quence of C-Cadherin depletion.
The Control of Cadherin Levels by EpCAM Is
Posttranscriptional and Involves Endocytosis
While EpCAM depletion caused a dramatic decrease in C-cad-
herin protein levels, it did not affect its mRNA levels (nor any of
the tested related molecules, E-cadherin, a- and b-catenin; Fig-
ure S2D), indicating that the regulation occurs at a posttranscrip-
tional level. Once dissociated, EpCAM-depleted cells showed
typical signs of apoptosis (caspase 3 activation, Figure S2E,
DNA cleavage, data not shown). However, C-cadherin overex-
pression was sufficient to rescue cell-cell adhesion (Figure 2B)
and to block caspase activation (Figure S2E), indicating that
apoptosis was not the cause but rather the consequence of
cadherin loss and cell dissociation. C-cadherin disappearance
from EpCAM-depleted cells appeared to be preceded by a
massive shift from plasma membrane to intracellular spots
(Figure 2E), indicating strong increase in cadherin internaliza-
tion. Consistent with degradation via the endocytic-lysosomal
pathway, C-Cadherin levels and tissue integrity could be
restored and LEI rescued by inhibiting dynamin (Figures S2F
and S2G).
EpCAM Promotes Cadherin-Mediated Adhesion by
Repressing PKC Signaling
We have shown that EpCAM depletion caused an increase in
PKC activity, which was responsible for the observed defective
epiboly (Maghzal et al., 2010). We confirmed that the levelsded by wild-type cells showed smooth contours (arrows) in contrast with the
E0 and H0) Cadherin levels were normal in COMO-injected cells, but lower in
. Single red channel (E0 and H0 ) shows the strong decrease in cadherin levels in
l maintained contacts with neighboring wild-type cells, but already showed
esoderm, and endoderm). The yellow line indicates limit between EpCAM MO
esoderm; ne, neuroderm; and som, somites. Scale bar, 50 mm.
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Figure 2. Loss of Integrity of EpCAM-
Depleted Ectoderm Explants
(A) Animal explants were dissected at the early
gastrula stage. These explants typically heal into
balls of undifferentiated ectoderm tissue com-
posed of an outer pigmented layer of polarized
epithelial cells surrounding an inner mass of
nonpolarized cells. After overnight culture (corre-
sponding to early tailbud stage in control em-
bryos), control explants were all still intact (A0 ),
but EpCAM MO-injected explants systematically
burst (A00).
(B) Quantification of LEI, i.e., percentage of
bursting explants. Integrity could be rescued by
coinjection of mRNA coding for wild-type Xenopus
or human EpCAM. However, Xenopus EpCAM
variants lacking either the cytoplasmic tail (DC) or
the extracellular domain (DE) failed to rescue.
Numbers on top indicate total number of explants
displaying LEI/total number of injected explants. In
all LEI experiments presented, each independent
experiment included ten explants per condition,
except for a few cases where one of the conditions
had 9 or 11 explants. Error bars, SD. **p < 0.001
compared to EpCAM MO (Student’s t test). NS,
not significant.
(C) EpCAM and C-cadherin levels in explants
extracted at neurula stage, i.e., before visible
bursting. EpCAM MO caused almost complete
loss of EpCAM, and concurrent strong decrease in
cadherin levels. The result was reproduced in eight
independent experiments.
(D–F) Cadherin immunostaining on sections of
control and EpCAM-depleted explants. The ex-
periment was repeated three times. (D) In control
explants, plasma membranes were typically
decorated with cadherin ‘‘puncta’’ (white arrrow-
heads). (E) Already at stage 16 (early neurula),
EpCAM depletion led to reduction (yellow arrow-
heads) and even total disappearance (red arrow-
heads) of plasmamembrane cadherin signal, while
numerous cadherin positive intracellular spots
appeared (yellow arrows). (E0) enlarged area. The
position of the plasma membrane is highlighted
with a red dashed line, and white arrowheads to
corresponding cadherin puncta. (F) By late neurula
(stage 19), the cadherin signal had almost dis-
appeared. Scale bars, D–F, 10 mm; E0, 5 mm.
See also Figure S2.
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Direct Inhibition of PKC by EpCAMof several phosphorylated PKC substrates (pPKCsub) were
abnormally elevated in EpCAM-depleted ectoderm explants
(Figure 3A, arrows). We thus hypothesized that cadherin down-
regulation and loss of adhesion at later stages may similarly
result from PKC overactivation. Indeed, treatment of EpCAM-
depleted explants with bisindolylmaleimide (Bis1), a general in-
hibitor of classical and nPKCs, rescued LEI, and C-cadherin
levels (Figures 3D and 3E). PKCs are grouped into three classes:
classical PKCs (a, b, and g) are activated by calcium and diacyl-
glycerol; nPKCs (d, ε,and h) are activated by diacylglycerol
independently of calcium; and atypical PKCs by different mech-
anisms. Out of a panel of PKC inhibitors, thosewith specificity for
nPKCs tended to rescue LEI better than inhibitors of classical
PKCs (Figure 3D). Thus, similar to the effect on early morphoge-
netic movements (Maghzal et al., 2010), repression of nPKCs by266 Developmental Cell 27, 263–277, November 11, 2013 ª2013 ElsEpCAM appeared to be required for stabilization of cell-cell
adhesion. The fact that general PKC inhibitors such as Bis1 or
Calphostin C gave somewhat weaker rescues thanmore specific
nPKC inhibitors is likely due to their pleiotropic interference with
multiple cellular function, which was expected to have delete-
rious effects. In fact, we had to titrate each inhibitor used in
this work to compromise with their ‘‘toxicity’’ effects.
We also examined the link between EpCAM, PKCs, and
cadherins in Caco-2 cells, a human colon cancer cell line that
expresses high levels of EpCAM (Trebak et al., 2001; Ammons
et al., 2003; Maaser and Borlak, 2008). We similarly detected
a large increase in pPKCsub in EpCAM-depleted Caco-2
cells (Figures 3B and 3C), and a concomitant decrease in
E-cadherin levels (Figure S3), which could be rescued by inhibi-
tion of PKC.evier Inc.
A B C
D E
Figure 3. EpCAM Regulates PKC Activity in Embryos and in Cancer Cells
(A) Immunoblot detection of PKC activity in embryo extracts, using an antibody recognizing phosphorylated PKC substrates (pPKCsub). The signal was increased
for a subset of bands upon EpCAM depletion (examples shown with arrows), which was rescued by a coinjection of an mRNA coding for the PKCd pseudo-
substrate polypeptide (dnPKCd). Arrowheads point to bands that remained unchanged. Asterisk denotes band responding to EpCAMMO/dnPKCd, but saturated
on this image. Commassie staining was used as loading control. Five independent replicates.
(B) Immunoblot detection of PKC activity in Caco-2 cells. Caco-2 cells were transfectedwith anti-EpCAMsiRNA, and extracted 2 days later. Amassive increase in
pPKCsub signal is observed (arrows). Three independent replicates.
(C) Immunofluorescence detection of PKC activity in Caco-2 cells. siRNA-transfected cells were double stained for EpCAM and pPKC substrates. EpCAM
depletion led to a general increase in pPKCsub signal, including in the nucleus (arrowhead) and at the plasma membrane (arrow). The signal was abrogated by a
2 hr treatment with the PKC inhibitor calphostin C. Three independent replicates. Relative intensities of pPKCsub are represented as pseudocolors in the lower
panels. Scale bar, 10 mm.
(D) LEI depends on nPKCs. Explant integrity could be rescued by a generic PKC inhibitor (Bis1) and most efficiently by inhibitors specific to nPKCs (d and h).
Calphostin (PKCg+d) and Go¨6976 (PKCa, b, and g) hadmoderate effects and PKC 20-28 (PKCa and b) none. Error bars, SD. **p < 0.001 compared to EpCAMMO
(Student’s t test). NS, not significant.
(E) PKC and Erk inhibitors rescue cadherin levels in EpCAM-depleted explants. EpCAM MO-injected explants were treated with Bis1 (PKC) and pep1 (Erk)
inhibitors. Graph represents relative C-cadherin levels ± SD. *p < 0.05 and **p < 0.01, inhibitors compared to untreated EpCAM MO. Three independent
replicates.
See also Figure S3.
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Direct Inhibition of PKC by EpCAMLEI Is Caused by Increased Actomyosin Contractility
EpCAM depletion led to increased phosphorylated myosin light
chain (pMLC; Figure 4A), which prominently accumulated at
the cell cortex (Figures 4B and 4C). An increase in pMLC was
also observed in EpCAM-depleted Caco-2 cells (Figure 4A).
The actomyosin cytoskeleton appeared globally disorganized,Developmefurther emphasizing the severity of the phenotype (Figure S4).
Cortical tension produces a force that works antagonistically to
cell-cell adhesion (e.g., Sahai and Marshall, 2002; Lecuit,
2008). We therefore hypothesized that exacerbated contractility
of the cortical actin cytoskeleton could be the cause for desta-
bilization of adhesion and LEI. Consistently, adhesion andntal Cell 27, 263–277, November 11, 2013 ª2013 Elsevier Inc. 267
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Figure 4. LEI in EpCAM-Depleted Tissues Is Caused by Increased Myosin Contractility Downstream of PKC
(A) EpCAM depletion causes increased myosin light chain phosphorylation (pMLC). Graph represents relative pMLC levels ± SD. *p < 0.05 and **p < 0.01,
compared to COMO/siCTL.
(B–D) Accumulation of pMLC at the cell cortex of EpCAM-depleted cells. (B and B0 ) Section of mosaic whole embryo. EpCAM MO-injected cells were traced by
expression of membrane targeted Myc-GFP (B, Myc staining, red). B0. Phospho-myosin light chain (pMLC) showed prominent accumulation at the periphery of
injected cells (arrowheads). Three independent replicates. (C and C0) Sections of ectoderm explants, injected with control (C) or EpCAM MO (D) and stained for
pMLC. Cortical staining (arrowheads) is weak in controls and strongly increased in EpCAM-depleted cells. Three independent replicates. Scale bars, (B), 50 mm
(legend continued on next page)
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Direct Inhibition of PKC by EpCAMcadherin levels were rescued in EpCAM-depleted explants upon
inhibition of Rho, ROK, MLCK, or direct inhibition of myosin II
ATPase activity with blebbistatin (Figure 4D and 4E; Figure S4),
while expression of a constitutively active RhoA construct phe-
nocopied EpCAM MO-induced loss of adhesion and cadherin
depletion (Figures 4E–4G).
We finally confirmed in the whole embryo that inhibition of
nPKCs, myosin inhibition or C-cadherin overexpression were
each on its own sufficient to compensate for loss of EpCAM, effi-
ciently restoring tissue integrity (Figure 4H). Quite amazingly, the
embryos rescued by dominant negative PKCd and C-cadherin
developed almost normally (Figure 4H). Embryos rescued with
blebbistatin had more severe morphological defects (data not
shown), as expected from downregulating myosin activity, yet
most embryos did not show any epithelial disruption (Figure 4H0).
We conclude that upregulation of myosin activity by nPKCs is
responsible for cadherin depletion and can account for the
defects caused by loss of EpCAM.
Increased Contractility and LEI Result from Erk
Overactivation
While there was no obvious reported link between PKC and the
Rho-ROK pathway, a clear connection existed with another well-
established parallel branch of myosin activation through Erk-
MLCK (Nguyen et al., 1999). This pathway can indeed be
stimulated by phosphorylation of PKD/PKCm, a direct target of
nPKCs, which in turn activates the Raf-MAPK-Erk pathway (Fig-
ure 5A; Rozengurt et al., 2005; Wong and Jin, 2005). We found
that EpCAM depletion indeed led to nPKC-dependent overacti-
vation of PKD/PKCm and Erk (Figure 5) and that in EpCAM MO
explants, there was an enhanced phosphorylation of PKD/
PKCm at a PKC-specific site (Figure 5B). Erk phosphorylation
was similarly boosted (Figures 5C and 5F; Figure S5A), while
basal pErk levels were strongly reduced by EpCAM overexpres-
sion (Figure S5B). We verified that the effect of EpCAM depletion
on PKD and Erk was dependent on nPKCs, and that Erk and
MLC phosphorylation depended on the PKD-Raf pathway:
indeed nPKC inhibitors efficiently rescued pPKD and pErk levels
(Figures 5B and 5C; and Figure S5C), and pErk and pMLC levels
were rescued by PKD or Raf inhibition (Figures 5C, 5D, and 5F).
LEI was also rescued upon inhibition of PKD (Figure 5E), Raf, or
Erk (Figure 5H). Finally, cadherin downregulation was blocked
when the pathway was inhibited (Figures 3E and 5G). EpCAM
depletion caused a similar overactivation of nPKC and Erk in
human colon cancer Caco-2 and SW480 cells (Figure 5C; Fig-
ures S5D and S5E).and (C), 20 mm. (D) Cadherin levels are rescued by treatment of EpCAM-deple
C-cadherin levels ± SD. *p < 0.05 and **p < 0.01, bleb compared to untreated E
(E) Rescue of tissue integrity by inhibitors of myosin light chain kinase (ML-7) and
(caRho). Error bars, SD. **p < 0.01.
(F) Examples of control and caRho-expressing explants undergoing LEI. The exp
(G) caRhoA expression stimulates MLC phosphorylation and reduces cadherin le
(H) In vivo rescue of tissue integrity by expression of dominant negative PKCd,
injected in the animal ventral side with control (COMO), EpCAM MO, or EpCAM
EpCAMMO-injected embryos were also treated from early gastrula onward with b
General development was largely normal for dnPKCd-inhibited and C-cadherin r
treated embryos, the embryo morphology was rather severely perturbed (not
(H0) Quantification of three independent experiments. Error bars, SD. *p < 0.01 a
See also Figure S4.
DevelopmeThe Cytoplasmic Tail of EpCAM Directly Binds nPKCs
and Acts as a Pseudosubstrate Inhibitor
Optimal PKC substrate consensus sequences are all character-
ized by a cluster of basic residues positioned N-terminal to the
Ser/Thr, although other features vary between PKC isoforms
(Newton, 2001; Nishikawa et al., 1997). PKCs themselves display
a short motif resembling a substrate sequence, but lacking
the phosphorylatable Ser/Thr (Newton, 2001). In their inactive
conformation, PKCs are folded in such away that thismotif binds
to the catalytic domain and acts as an internal pseudosubstrate
inhibitor. Upon activation, the conformational change produced
by phospholipids and diacylglycerol DAG binding relieves the
autoinhibition.
The cytoplasmic tail of EpCAM (EpTail) is required for EpCAM
function because adeletionmutant fails to rescue LEI (Figure 2B).
We discovered that this 24-amino-acid-long tail contained a
highly conserved stretch adjacent to the transmembrane domain
that resembled quite strikingly a typical pseudosubstrate motif,
more specifically the motifs of two nPKCs, PKCd and PKCh (Fig-
ure 6A). This surprising feature suggested that the juxtamem-
brane motif (JM; Figure 6A) of the EpCAM may directly bind
and inhibit nPKCs. Coimmunoprecipitation experiments in
Caco-2 cells showed that endogenous PKCd and EpCAM phys-
ically interact in vivo (Figure 6B) and recombinant GST-EpTail
could pull down at least two PKC isoforms from Xenopus
extracts, one of which was identified as PKCd (Figure 6C). To
demonstrate that the interaction was direct, we repeated the
pull-down experiments using pure lipid-activated recombinant
PKCs. GST-EpTail bound efficiently PKCd and PKCh but not
classical PKCb (Figure 6D). PKCd and PKCh could also bind to
GST fusions of the JM alone, as well as to peptides correspond-
ing to the equivalent human and Zebrafish JM sequences (Fig-
ure 6D). The interaction could be efficiently competed by an
excess of PKCh pseudosubstrate peptide (Figure 6E), consis-
tent with EpCAM tail interacting with the substrate binding sur-
face of the PKC catalytic domain. We used surface plasmon
resonance spectroscopy (SPR) to obtain quantitative data on
EpCAM-PKC interactions. Human, Xenopus and Zebrafish
EpCAM JMs bound PKCd with affinity constants of 40–60 nM,
in the range of the valuemeasured for the ownPKCd pseudosub-
strate (Figure 6F), and Xenopus JM bound to PKCh with a Kd of
30 nM (data not shown). These results demonstrate that EpCAM
functions as a direct and strong pseudosubstrate inhibitor of
nPKCs.
We thus expected that EpTail would similarly inhibit PKC activ-
ity. We assayed PKC phosphorylation in vitro using recombinantted explants with the myosin inhibitor blebbistatin. Graph represents relative
pCAM MO.
myosin ATPase (blebbistatin), and induction of LEI by constitutively active Rho
eriment was repeated four times.
vels. The experiment was repeated three times.
by cadherin overexpression, or by treatment with blebbistatin. Embryos were
MO and mRNA coding for C-cadherin or for dominant negative PKCd. Some
lebbistatin. The formation of lesions was blocked in each of the three rescues.
escued embryos. Blebs near the head are injection artifacts. For blebbistatin-
shown), but no epithelial lesion was observed, and the embryos hatched.
nd **p < 0.001 compared to EpCAM MO (Student’s t test).
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Figure 5. Upon EpCAM Depletion, LEI Involves Activation of the Erk Pathway via PKD/PKCm
(A) Summary diagram of the pathway: EpCAM inhibits nPKCs, which otherwise activate PKD/PKCm, which in turns stimulate the Erk pathway. Phosphorylated Erk
phosphorylates/activates MLCK, and thus MLC. Overactivated myosin destabilizes adhesion and causes decrease in cadherin levels.
(B) Increased PKD/PKCm phosphorylation in EpCAMMO explants and rescue by dnPKCd. Error bars, SD. *p < 0.05 and **p < 0.01, dnPKCd compared to EpCAM
MO, three replicates.
(C) Stimulation of Erk phosphorylation in EpCAM-depleted Xenopus explants and Caco-2 cells, rescued by dnPKCd and by Raf inhibitor. Error bars, SD. *p < 0.05
and **p < 0.01, inhibitors compared to EpCAM MO, three replicates.
(D) PKD inhibition rescues pErk and pMLC levels in EpCAM-depleted tissues. Error bars, SD. *p < 0.05, PKD-i compared to EpCAM MO, three replicates.
(E) Dose-dependent rescue of tissue integrity by treatment with PDK inhibitor. Error bars, SD. *p < 0.05. NS, not significant, three replicates.
(legend continued on next page)
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Direct Inhibition of PKC by EpCAMPKCd and a recombinant form of its classical substrate, myelin
basic protein (Kishimoto et al., 1985). We found that the addition
of GST-EpTail inhibited PKCd activity (Figure 7A).
PKC substrate sequences are typically characterized by basic
amino acids flanking on one or both sides the phosphorylatable
serine/threonine, and the EpCAM JM included such residues at
positions identical to those of optimal nPKC susbtrates (Fig-
ure 6A). Substituting two residues of the basic cluster of EpTail
with uncharged resides (NQ, Figure 7B) strongly decreased
PKC binding (Figure 7C). An equivalent variant of full-length
EpCAM failed to rescue LEI in EpCAM-depleted explants (Fig-
ure 7D). The same result was obtained with another variant
harboring an additional substitution of lysine +3 (NQE, Figure 7D).
These two mutants also failed to rescue cadherin levels (Fig-
ure 7E). Both mutants were expressed at levels at least equal
to wild-type EpCAM (not shown). These results demonstrated
that specific residues of EpCAM JM implicated in PKC binding
were necessary for in vivo EpCAM function.
We alsomodeled the 3D structure of active PKCd bound to the
human EpCAM JM (Figure 7F). The model predicts an intimate
and extended association of the JM to the groove of the catalytic
site, readily explaining the high affinity of this interaction. The
model also predicts EpCAM-bound PKCs to be tightly apposed
to the lipid bilayer, thus further impairing substrate accessibility.
This suggests that the EpCAM JM has been optimized for effi-
cient inhibitory activity toward nPKCs.
The Juxtamembrane Domain of EpCAMDefines a Group
of PKC-Binding Transmembrane Proteins
Charged amino acids are systematically found on both sides of
the transmembrane domains of membrane proteins, where
they serve to ‘‘clamp’’ the hydrophobic helix into its correct
position. On the cytoplasmic side, these residues are most
frequently basic. Since basic residues are essentially the hall-
mark of PKC substrates, we wondered whether cell-surface pro-
teins other than EpCAMmay similarly bind PKCs. Our molecular
model indicated that, in addition to the three to four basic
consecutive residues, several other specific interactions consti-
tuted part of the PKC-interacting domain of the EpCAM JM,
consistent with the strict conservation of most residues of the
JM motif from Xenopus to mammals (Figure 6A; Table S1). To
get some indication about the stringency of the requirements,
we tested a series of GST-EpTail point mutation variants by
in vitro pull-down (Figure S6) and surface plasmon resonance
(Figure S7). While no single mutation abolished PKC binding,
some features appeared to be important for maximal interaction.
Based on the EpCAM sequence conservation, predictions
from the molecular modeling, and these experimental results,
we defined an approximate consensus sequence, which we
used to interrogate the human proteome sequence database.
Because we were more specifically interested in cell-surface
proteins, we narrowed the search to sequences that would
closely follow a transmembrane helix, thus corresponding to
bona fide JMs. The search identified several JMs with high sim-(F and G) Raf inhibition rescues pMLC and cadherin levels in EpCAM-depleted tis
three replicates.
(H) Rescue of tissue integrity by Raf or Erk (pep1) inhibition. Error bars, SD. **p <
See also Figure S5.
Developmeilarity to the nPKC-binding consensus motif (examples in Fig-
ure 8A; complete list in Table S2). Quite remarkably, most of
the top ranked sequences belonged to known or hypothesized
cell-cell adhesion molecules. We tested three of the candidate
JMs—EphA4, ICAM1, and NrCAM (taken from the top, middle,
and bottom, respectively, of the list presented in Table S2)—in
the in vitro pull-down assay (Figure 8B), and found that all three
sequences bound PKCd and PKCh. EphA4, which had highest
similarity score relative to the EpCAM consensus sequence,
was also the best interactor. We validated the potential for
PKC inhibition of EphA4 by expressing the wild-type protein in
ectoderm explants, which have very low endogenous levels of
this receptor, and indeed observed a significant reduction
(50%) of phosphorylated PKD (Figure 8C). We conclude that
EpCAM belongs to a group of evolutionary unrelated plasma
membrane proteins that can sequester PKCs via a short pseudo-
substrate-like juxtamembrane motif.
DISCUSSION
In this study, we provide a mechanistic explanation for EpCAM
function in tissue morphogenesis, and uncover a mode of nega-
tive regulation of intracellular signaling by cell-surface proteins.
Myosin Regulation Accounts for EpCAMMorphogenetic
Function
EpCAMdepletion caused a dramatic deregulation of intracellular
signaling, as evidenced by the increased phosphorylation of
multiple PKC substrates and the massive Erk activation. It is
likely that this global activation had pleiotropic effects, including
on gene transcription via modulation of nuclear PKC and Erk.
Yet, we could rescue surprisingly well all embryonic phenotypes
by acting on a handful of molecules, which could be all placed
along a straightforward pathway.While multiple branches down-
stream of PKCs, PKD or Erk may be controlled by EpCAM (cad-
herin is, for instance, a direct target of PKD; Jaggi et al., 2005),
myosin activation downstream of Erk appears sufficient to
account for the observed phenotypes. The fact that tissue integ-
rity could be rescued by simply incubating EpCAM-depleted
embryos with blebbistatin was a particularly striking direct
demonstration of the importance of myosin regulation by
EpCAM. Regulation of nPKC-PKD-Erk-myosin pathway may
also satisfactorily explain the adhesive defects observed in
EpCAM-1/ zebrafish embryos (Slanchev et al., 2009) and in
the intestinal epithelium of mouse EpCAM-1 knockout (Lei
et al., 2012). In both cases, the milder phenotypes can be ex-
plained by the presence of a second EpCAM. Two pseudo-
alleles are also present in Xenopus (Maghzal et al., 2010), and
both had to be targeted in our loss-of-function experiments to
observe LEI.
Despite the general disorganization of the actin cytoskeleton
in EpCAM-depleted cells, the most acute effects were clearly
concentrated at the cell periphery (see pMLC and actin accumu-
lation; Figures 4B and 4C; Figure S4C). This is certainlysues. Error bars, SD. *p < 0.05 and **p < 0.01, Raf-i compared to EpCAM MO,
0.01.
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Figure 6. The Juxtamembrane Region of
EpCAM Cytoplasmic Tail Corresponds to a
Pseudosubstrate-like Motif that Directly
Binds nPKCs
(A) Alignment of the juxtamembrane region (JM) of
Xenopus (x), human (h) and Zebrafish (z) EpCAMs,
nPKC substrate consensus and pseudosubstrate
sequences (Steinberg, 2004). Residues replacing
the phosphorylated Ser/Thr at position p = 0 are
underlined. Amino acid residues are color-coded
based on their general chemical properties.
Conserved tyrosine in EpCAM and corresponding
phenylalanine at P+1 of PKC substrates are high-
lighted by a blue background, basic residues on
both sides of p = 0 in pink, and hydrophobic resi-
dues in +4 in gray. ‘‘TM’’ indicates the end of the
transmembrane domain in the EpCAM sequences.
The two last rows present the approximate con-
sensus sequences based on sequence compari-
son of various vertebrate EpCAMs (see Table S1)
and on the results of pull-down experiments using
mutated JM fusions (see Figure S6).
(B) EpCAM and PKCd interact in vivo. EpCAM was
immunoprecipitated from Caco-2 cell extracts,
and the precipitate was probed for PKCd. The
experiment was replicated four times.
(C) In vitro interaction between endogenous PKCs
from a Xenopus embryo extract and recombinant
EpCAM cytoplasmic tail fused to GST (xTAIL).
Bound PKCs were detected by immunoblot: A
pan-PKC antibody recognized three bands in ex-
tracts, two of which were recovered in the xTAIL
bound fraction (arrowheads). The presence of
PKCd in this fraction was demonstrated using an
isoform specific antibody. The experiment was
replicated five times.
(D) Direct in vitro binding of recombinant PKCd and
PKCh to cytoplasmic tails of Xenopus, human and
Zebrafish EpCAM. Purified activated PKCs were
incubated with GST fusions of the complete
Xenopus EpCAM tail (xTAIL), of the 13 amino acids
of its juxtamembrane domain (JM), or the equiva-
lent sequence from human and Zebrafish EpCAM2
(see A). GST was used negative control. The
experiment was replicated three times.
(E) EpCAM-PKC interaction is competed by PKC
pseudosubstrate. Direct in vitro pull-down was
performed in the presence of 1003 excess of a
peptide corresponding to the pseudosubstrate
region of PKCh. The experiment was replicated
three times.
(F) Surface plasmon resonance affinity measure-
ment for EpCAM juxtamembrane domains (GST-
fusion proteins) toward PKCd (immobilized activated recombinant PKCd). Dissociation rates and relative binding capacities were determined frommeasurements
with a fixed GST concentration (500 nM) in the multi-cycle mode. Dissociation constants were measured from kinetic titrations in single-cycle mode using low-
density PKC surfaces. The human form (hJM) has the highest affinity (lowest KD), the highest dissociation rate (kd) and the highest binding capacity, followed by
the Xenopus form (xJM) and last by the Zebrafish peptide (zJM), fully consistent with the pull-down data. The PKCd pseudosubstrate showed values similar to
zJM. The PKCh pseudosubstrate had an atypical behavior, with low binding capacity and very slow dissociation, perhaps explaining the strong binding observed
in the pull-down assay, where interaction is measured after repeated washing steps. Its KD could not be determined with enough accuracy.
See also Figures S6, S7, and Table S1.
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Direct Inhibition of PKC by EpCAMconsistent with the cell membrane localization of EpCAM and its
direct mode of inhibition of PKCs, which is likely to affect primar-
ily processes occurring in its immediate vicinity. The fact that
cadherin overexpression was sufficient to fully rescue explant
and embryo LEI (Figures 2B and 4H) is another strong argument
suggesting that as far as cell behavior and morphogenesis are272 Developmental Cell 27, 263–277, November 11, 2013 ª2013 Elsconcerned, the cell membrane and the underlying cortex are
themajor targets of the repressive control by EpCAM. The selec-
tivity of EpCAM for nPKC is in agreement with the abundant
literature describing this subclass of kinases as regulators of
the actin cytoskeleton and of cell adhesion (Newton, 2001;
Le et al., 2002; Kinoshita et al., 2003; Steinberg, 2004; Iwabuevier Inc.
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Direct Inhibition of PKC by EpCAMet al., 2004; Chen and Chen, 2009; Singh et al., 2009; Rosse
et al., 2010).
The simple membrane localization of the EpCAM does not
seem to be sufficient to fully explain its regulatory function.
Indeed, while DE-EpCAM was capable to efficiently rescue cell
motility and epiboly (Maghzal et al., 2010), we found that this
variant could not rescue LEI. We presume that the extracellular
domain was here required for a more refined control of myosin
activity, perhaps by contributing to localize EpCAM to particular
membrane sites/subdomains. Future studies should determine
the potential role of cis- or trans-, homophilic, or heterophilic
interactions, and establish the exact site of action of EpCAM.
EpCAM may need to be present at high levels near cadherin
adhesion junctions, or on the contrary should be located at
distinct sites to sequester nPKCs away from adhesive struc-
tures. Costaining for EpCAM and C-cadherin gave a complex
picture of colocalization in some regions but mutual exclusion
in others, thus compatible with both possibilities (data not
shown).
EpCAM, a Promoter of Adhesion and Migration
EpCAM promotes cell adhesion as well as cell migration, but in
the absence of a molecular explanation, the apparent opposition
of these effects has remained a puzzle.We provide amechanism
that satisfactorily reconciles all observed phenotypes: by
impinging on Erk signaling via nPKCs and PKD, EpCAM tempers
actomyosin contractility, creating a general condition favorable
for cell motility as well as for cell adhesion. Migration and cell
adhesion are often viewed as opposite properties, but they are
in fact interdependent and both need the right amount of
myosin-driven contractility. Some contractility is required to sta-
bilize adhesive and protrusive structures, which accounts for the
well-established promigratory activity of Erk (reviewed in Huang
et al., 2004), but elevated cortical tension is in all cases resolutely
antagonistic to both migration and adhesion. This can be intui-
tively explained as follows: while adhesion increases cell-cell
contact surface, actomyosin-driven contractility of the cell cor-
tex tends on the contrary to minimize cell surface, forcing the
cell into a spherical shape, and thus decreasing cell-cell contact
(see e.g., Sahai and Marshall, 2002, Lecuit, 2008). The same
need for balanced cytoskeletal properties applies for cell-cell
and for cell-matrix adhesion, which explains the positive role of
EpCAM on both modes of adhesion (Gostner et al., 2011; Magh-
zal et al., 2010; Osta et al., 2004; Slanchev et al., 2009; Tsuka-
hara et al., 2011; Villablanca et al., 2006; our present results
and unpublished data). By stimulating cell movement while
ensuring tissue coherence at the same time, EpCAM creates
ideal conditions for high tissue dynamics.
Our loss-of-function experiments reveal that EpCAM is a
particularly potent morphoregulator: the observed doubling of
total levels of phosphorylated Erk and myosin, complete loss
of cadherin, cell rounding-up and detachment, are all quite
drastic embryonic phenotypes. Although physiological changes
in EpCAM levels may not always be as abrupt as those produced
in our experimental depletions, they can reach equivalent ampli-
tudes, both in cancer (Munz et al., 2009) and during normal
embryonic development (Figure S1A).
EpCAM properties make it certainly an attractive candidate for
selection in tumors. For instance, high EpCAM may allow cellDevelopmegroups with high migratory properties to maintain cell-cell con-
tacts, a clear advantage for invasion through collective cell
migration. High EpCAM may also buffer high contractility at the
cell cortex, for instance in case of Erk overactivation, a common
property of invasive cells. However, it is unlikely that the basic
mechanism uncovered in this study can be directly translated
into a simple diagnostic applicable to all EpCAM-overexpressing
cancer cells. We predict that the effect on migration and adhe-
sion will also depend on a variety of other parameters, including
the degree of PKC activation by other pathways, or basal cell
contractility/rigidity. In the embryo, for instance, the ectoderm
is intrinsically stiffer than mesoderm, which could explain why
the former is particularly sensitive to EpCAM loss. We expect
that similar differences will modulate EpCAM function in various
cell types and different stages of cancer progression.
Direct PKC Inhibition by Cell-Surface ‘‘Receptors’’
Mechanistically, the mode of action of EpCAM is rather remark-
able for a plasma membrane protein. Its juxtamembrane domain
has evolved to mimic with exactitude the optimal pseudosub-
strate sequence of nPKCs, a similarity that not only provides
EpCAM with strong PKC inhibitory capacity, but also confers
high specificity for the nPKC isoforms d and h compared to
PKCb. Note that in our binding experiments the PKCd and h
did not show the strict specificity for their own pseudosubstrate
that is generally assumed. As for EpCAM, it binds nPKCs about
as efficiently as the pseudosubstrates, and its affinity in the
nanomolar range indicates a powerful inhibitory capacity. The
positioning of the pseudosubstrate-like motif very close to
the plasma membrane is particularly optimal for local scav-
enging of membrane-bound activated PKCs (Figure 7F), and
EpCAM is thus predicted to compete even more efficiently
with PKC substrates under the conditions of the intact cells. In
addition to the tight sequestration of the catalytic site, molecular
modeling suggests potential additional constrains due to the
vicinity to the lipid bilayer, which are expected to further hamper
access to protein substrates, thus reinforcing the efficiency of
the inhibition. Potential mechanisms regulating this interaction
will be an obvious question to address in the future. Another
interesting related question would be to determine whether an
EpCAM-bound PKCmay still be eventually released in the active
form. Alternatively, PKCs may remain sequestered until eventu-
ally inactivated by loss of their lipid anchors, then released and
potentially degraded. This latter possibility could then represent
some sort of ‘‘catalytic’’ function of EpCAM in PKC deactivation,
in which case one EpCAM may repress more than one PKC
molecule, thus contributing to the observed massive repression.
We found that EpCAM is probably not the only plasma mem-
brane protein that can bind PKCs, but rather an example of a
larger group of potential PKC regulators. The top list of the can-
didates identified by our search includes a variety of gene fam-
ilies evolutionary unrelated to each other. However, the list
includes many functionally related candidates (see annotations
of Table S2). The largest group consists of CAMs. It includes at
least 16 cell-cell or cell-matrix adhesion molecules (annotated
as ‘‘CAM’’), as well as several predicted CAMs of ‘‘CAM-like’’
(annotated as ‘‘(CAM)’’). Altogether, CAMs represent more than
half of the 37 proteins with scores above 5. A second over-rep-
resented category (seven candidates) groups transmembranental Cell 27, 263–277, November 11, 2013 ª2013 Elsevier Inc. 273
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Figure 7. The Juxtamembrane Region Inhibits PKC and Is Required for EpCAM Function
(A) The EpCAM cytoplasmic tail directly inhibits PKC activity. In vitro kinase activity of PKCd was determined by monitoring the phosphorylation levels of myelin
basic protein (MBP) on immunoblots using the pPKCsub antibody. Addition of increasing amounts of recombinant xTAIL, but not of control GST, inhibited MBP
phosphorylation in a dose-dependent fashion. The p values are compared to GST. (A0) Quantification. Average MBP phosphorylation levels (three independent
experiments) are expressed as ratio to controls, ± SD.
(B–E) JM basic residues are required for rescue of LEI and of cadherin levels. (B) Sequence of the JMof two EpCAMvariants with substitutions of basic residues at
positions3 and2 (NQ) or3,2, and +3 (NQE). (C) In vitro pull-down illustrating the strongly decreased binding of NQ compared to the wild-type EpCAM tail
(FL). (D) Both NQ and NQEmutants failed to rescue LEI. (E) NQ and NQE failed to rescue cadherin levels in EpCAMMO-injected tissues. Quantification was from
three independent experiments. Error bars, SD. **p < 0.01 compared to EpCAM MO alone. NS, not significant.
(F and F0 ) Model of activated human PKCd kinase bound to ATP and to the juxtamembrane region ITNRRKSGKYKKVE of human EpCAM2. (F) Overall structure of
the known kinase domains: C2, C1A, C1B, and catalytic domain of the kinase linked to each other by flexible crosslinkers. C2, C1A, and C1B domains interact
with the lipid bilayer through association with diacylglycerol and phospholipids (not represented). The pseudosubstrate region of PKCd located upstream of
C1A domain is shown in ball-and-stick representation. The catalytic domain is shown with the bound peptide region (ball-and-stick representation) and
(legend continued on next page)
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Figure 8. Identification of Other Similar Juxtamembrane Sequences with PKC Binding Properties
(A) Alignment of the JMs from human EpCAM and from selected plasma membrane proteins identified by bioinformatics search. Relative ranks are indicated in
the first column. See Table S2 for the complete list.
(B) JMs of EphA4, ICAM and NrCAMbind nPKCs. Representative example of in vitro interaction pull-downs of PKCd and PKChwith GST fusions of EphA4, ICAM,
and NrCAM JMs. Coomassie staining showing levels of GST is used as loading control. The experiment was replicated three times.
(C) EphA4 inhibits PKD phosphorylation in vivo. EphA4 was expressed in ectoderm tissue, which led to an 50% reduction in pPKD levels in total lysates
prepared at late gastrula stage. Error bar, SD. *p < 0.05. The experiment was replicated four times.
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Direct Inhibition of PKC by EpCAMproteins typically involved in cell guidance (including Eph recep-
tors, plexin, DCC, and slit-like proteins). We have validated the
ability of one of them, EphA4, to inhibit PKC activity in vivo. A
potential role in specifically sequestering nPKCs may be again
consistent with the fact that all these candidate membrane pro-
teins interact in one way or the other with the actin cytoskeleton.
In addition, at least in the case of Eph receptors, these have been
shown to function as cell-cell adhesion molecules under certain
circumstances (Halloran and Wolman, 2006; Noren and Pas-
quale, 2004), further adding to the surprising coherence of this
list. We speculate that these various molecules locally regulate
PKC, each in a particular subcellular niche, and that there may
be then a particular need to dampen PKC activity at sites of con-transmembrane (TM) helix (ribbon) of EpCAM. Positively and negatively charged
respectively. The modeling reveals that the positively charged residues (in blue
residues (salmon color) of the kinase. The model suggests a positioning and orie
hold it in tight apposition to the membrane. (F0) A close-up view of the bound pept
(in blue). Oxygen, nitrogen, and phosphate atoms are in red, blue, and orange, re
by a red broken line. Note the tyrosine of position P+1 intimately fitting into a h
request.
Developmetact, a fascinating avenue to be pursued. The relative impact of
each regulator will certainly vary widely, e.g., according to the
relative affinity to PKCs, levels of expression and cell type, but
we believe that our findings open a potential important field of
investigation in signal regulation. Because the sequence require-
ments of PKC phosphorylation targets are somewhat flexible
(Marais et al., 1990; Kennelly and Krebs, 1991), it is likely that
our search has missed additional nPKC binding candidates
among the hundreds of juxtamembrane domains that contain
basic residues. Furthermore, there is no a priori reason to
exclude the existence of other related motifs specific for the
two other classes of PKCs, thus further expanding the potential
regulatory events occurring at such sites.residues on the surface of the kinase are shown by blue and salmon colors,
) of the bound peptide are surrounded by the clusters of negatively charged
ntation of the kinase catalytic domain relative to EpCAM TM helix that would
ide (carbon atoms in green) in the binding pocket of the PKCd catalytic domain
spectively. Ionic or hydrogen bonds between peptide and kinase are denoted
ydrophobic pocket. The atomic coordinates of the model are available upon
ntal Cell 27, 263–277, November 11, 2013 ª2013 Elsevier Inc. 275
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Direct Inhibition of PKC by EpCAMThese results have uncovered am unexpected aspect of
EpCAM biology, which stands as an important regulator of intra-
cellular signaling. The discovery of this mechanism of PKC
repression opens a path toward understanding the exact impact
of EpCAM levels on cancer progression.
EXPERIMENTAL PROCEDURES
Embryo Manipulations
Xenopus laevis embryos were injected at early cleavage stages with antisense
Morpholino oligonucleotides targeting EpCAM and/or various mRNAs. Ecto-
derm explants were obtained by dissection of animal caps at the early gastrula
embryo and cultured overnight. Chemical inhibitors were added to themedium
during this overnight incubation. Loss of integrity was scored at the time when
control embryos reached the early tailbud stage. Biochemical and microscop-
ical analyses were carried out at the neurula stage, i.e., before the first signs of
tissue disruption.
Culture Cells
EpCAM was depleted in human colon cancer cell lines Caco-2 and SW480
cells by transfection of anti-human EpCAM siRNA (Santa Cruz Biotechnology).
Cell were extracted for biochemical experiments or fixed in 4% paraformalde-
hyde for immunofluorescence 48 hr posttransfection.
Quantitative Immunoblots
Samples were separated by SDS-PAGE, transferred on nitrocellulose mem-
branes, and incubated with primary and peroxidase-conjugated secondary
antibodies. The blots were developed using a chemiluminescent detection re-
agent (WBKL0500, Millipore) and images were captured with a 12-bit digital
camera (Alpha Innotech MultiImage system). Data were quantified using the
Gene Tools software (Syngene). Dilution series were used to verify the linearity
of the signal. Relative signal intensities were calculated as ratios to loading
controls. Statistical significance was calculated using Student’s t test.
In Vitro Pull-Down
Direct interaction between EpCAM and PKCs was determined using bacterial
recombinant GST fusions of EpCAM cytoplasmic tail or various variants and
recombinant his-tagged PKC activated by addition of PKC lipid activators.
Kinase Assay
PKC activity was measured in vitro using recombinant N-terminal 6His-tagged
PKCd (Millipore) as enzyme and recombinant Myelin Basic Protein (Santa Cruz
Biotechnology) as substrate. The reaction was supplemented with 0.3% Triton
X-100, 0.1mM CaCl2, PKC lipid activator (Millipore), an ATP regenerating sys-
tem, and phorbol 12-myristate 13-acetate (EMD). The reaction was started
with the addition of PKCd, and was carried out for 10 min at 30C for
10 min. It was stopped by adding 12.5 ml of 43 Laemmli sample buffer. Sam-
ples were analyzed by immunoblot with anti-phospho-(Ser) PKC substrate
antibody (Cell Signaling Technology).
Detailed experimental procedures, including surface plasmon resonance,
bioinformatics, and molecular modeling can be found in the Supplemental
Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.devcel.2013.10.003.
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